DC
BCRX icon

Deere & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Deere & Company’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-64,586
Closed -$667K – 1007
2015
Q4 		$667K Hold
64,586
– – 0.04% 427
2015
Q3 		$736K Buy
+64,586
New +$862K 0.05% 420
2015
Q1 		– Sell
-17,621
Closed -$214K – 970
2014
Q4 		$214K Sell
17,621
-18,323
-51% -$202K 0.01% 853
2014
Q3 		$352K Buy
+35,944
New +$441K 0.02% 755
2014
Q2 		– Sell
-53,520
Closed -$566K – 953
2014
Q1 		$566K Sell
53,520
-42,826
-44% -$457K 0.03% 585
2013
Q4 		$732K Buy
96,346
+6,219
+7% +$39.4K 0.04% 528
2013
Q3 		$656K Buy
+90,127
New +$457K 0.04% 523

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deere & Company's BCRX Position: Q1 2016 in Review

Deere & Company sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 64,586 shares — an estimated $667K sold.

Deere & Company first reported a position in BCRX in Q3 2013 and held it in 7 quarters. The position peaked at $736K in Q3 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

  • Deere & Company reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Deere & Company sold 64,586 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $667K.
  • Deere & Company first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Deere & Company's BioCryst Pharmaceuticals position peaked at $736K in Q3 2015.
  • 109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Deere & Company's 13F filing for Q1 2016, filed 9 May 2016.